Press Releases

LAVAL, Quebec --(BUSINESS WIRE)--Nov. 24, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

- Following a recent FDA meeting, the Phase 2b   SOOTHE trial in refractory chronic cough patients remains on track to initiate in Q4 2020 - - The Phase 2 BLUEPRINT trial in chronic pruritus associated with atopic dermatitis remains on track to initiate in Q4 2020 - - Recently completed $40M

LAVAL, Quebec --(BUSINESS WIRE)--Nov. 10, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

LAVAL, Quebec --(BUSINESS WIRE)--Oct. 22, 2020-- BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

Common Shares Priced at US$2.25 per Share LAVAL, Quebec --(BUSINESS WIRE)--Oct. 19, 2020-- In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today

LAVAL, Quebec --(BUSINESS WIRE)--Oct. 19, 2020-- BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Prospectus”)

- D ouble-blind, 4-week placebo controlled, parallel arm trial will evaluate the efficacy and safety of 3 doses of BLU-5937 in 280 patients with refractory chronic cough – - Trial to recruit patients with baseline cough count ≥25 coughs per hour -- RELIEF Phase 2 trial results demonstrated

LAVAL, Quebec --(BUSINESS WIRE)--Sep. 3, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

- Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020 - LAVAL, Quebec --(BUSINESS WIRE)--Aug. 13, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for

- Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance - - Highly statistically significant and clinically meaningful reductions in placebo adjusted awake cough frequency achieved in pre-specified analysis of high cough count patients